40
Participants
Start Date
March 31, 2013
Primary Completion Date
May 31, 2014
Study Completion Date
May 31, 2014
Aldesleukin (Proleukin)
A single, subcutaneous dose will be given administered with the maximum dose allowed 1.5 X 106 IU/M2.
Wellcome Trust Clinical Research Facility, Addenbrooke's Hospital, Cambridge
Collaborators (1)
University of Cambridge
OTHER
Juvenile Diabetes Research Foundation
OTHER
National Institute for Health Research, United Kingdom
OTHER_GOV
Wellcome Trust
OTHER
Cambridge University Hospitals NHS Foundation Trust
OTHER